CorMedix's (CRMD) near-term growth prospects will be shaped by upcoming clinical data, particularly around the potential use of Rezzayo to prevent invasive fungal infections in high-risk transplant and cancer patients, RBC Capital Markets said Tuesday in a report.

At the company's research and development event, clinicians said Rezzayo's clean safety profile, few interactions with other medications, high initial drug levels, and once-weekly IV dosing could make it well-suited for prophylaxis in immunocompromised patients, the report said. Management estimates the prophylaxis market at $2 billion, while RBC models about $150 million in potential revenue based on a 10% share.

Physicians also highlighted the drug's advantages in treating invasive fungal infections, noting that Rezzayo is currently used mostly in later-line settings, the report said. Broader adoption in treatment will likely require additional data and insurer coverage decisions, RBC said.

For DefenCath, management and panelists pointed to potential use in total parenteral nutrition patients, who face elevated infection risks and related complications, the report said.

RBC maintained its rating of outperform, speculative risk, on CorMedix with a $13 price target.

Price: 7.56, Change: -0.14, Percent Change: -1.76